CD19 and lymphoma: For CAR T cells, as rituximab appears effective for SSc treatment, it may be worth exploring B cell-depleting CAR T cells, e.g., CD19-directed CAR T cells that are commercially available for lymphomas and acute lymphoblastic leukemia.